证券代码：002690 证券简称：美亚光电 公告编号：2023-010 合肥美亚光电技术股份有限公司 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 投资者依据提示，授权登入"美亚光电投资者关系"小程序，即可参与交流。 出席本次年度报告说明会的人员有：副董事长兼总经理沈海斌女士、副总经 理兼财务总监张浩先生、董事会秘书程晓宏先生、独立董事储育明先生。 欢迎广大投资者积极参与。 特此公告。 1 合肥美亚光电技术股份有限公司董事会 2023年3月31日 2 合肥美亚光电技术股份有限公司（以下简称"公司"）已于2023年3月31日 披露《2022年年度报告》全文及摘要，为使投资者及时了解公司年度经营情况， 公司定于2023年4月12日下午15:00-17:00在"美亚光电投资者关系"小程序举办 2022年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者 可登录"美亚光电投资者关系"参与互动。为广泛听取投资者的意见和建议，提 前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信中搜索"美亚 ...

Group 1: Strategic Collaborations - The company signed a strategic cooperation framework agreement with the Shanghai Bone Tumor Research Institute on November 3, 2015, aimed at advancing new treatment technologies for bone and soft tissue tumors [3] - The collaboration focuses on the development of high-end medical imaging equipment and remote diagnosis services, with specific cooperation details to be announced later [3] Group 2: Product Development and Market Outlook - The X-ray packaging food detection series has matured and is currently on the market, with significant potential due to increasing food safety demands [4] - The company expects to meet its sales targets for the X-ray dental CT diagnostic machine series in 2015, with a stable market competition landscape [4][5] - The company is actively upgrading existing products while expanding into other specialized high-end medical imaging equipment [5] Group 3: Financial Insights - The increase in accounts receivable is primarily due to the implementation of credit sales for export customers, with cooperation from the China Export Credit Insurance Corporation to mitigate risks [4]

Group 1: Company Developments - The company has completed the research and development of orthopedic CT series equipment, currently in the testing and clinical phase, and plans to launch it after obtaining regulatory production licenses [2] - A strategic cooperation agreement has been signed with the Hefei Institute of Physical Science, aiming to enter the high-end precision radiotherapy industry, particularly proton therapy [3] - The company has undertaken a national major scientific instrument project, developing an infrared mass spectrometry device for early liver cancer detection [3] Group 2: Shareholder Actions - Company executives completed a stock purchase plan on November 16, 2015, with a total investment exceeding 10 million yuan, reflecting confidence in the company's future [3] - Since its listing, the shareholding of directors, supervisors, and senior management has remained stable without significant fluctuations [3] Group 3: Market Outlook - The industrial testing market includes various sectors such as ordinary industrial product testing, food safety, environmental testing, and security checks, with significant future demand expected due to increased safety regulations [4] - The company aims for sales revenue from the industrial testing sector to reach 30% of total revenue in the future [4] Group 4: Financial Strategy - The company plans to increase investments in high-end medical imaging and industrial testing, considering mergers or restructuring to enhance competitiveness and profitability [4]

Group 1: Export Business - The company's export business has seen a growth rate exceeding 50% in the first half of 2015 [2] - The international trade department has exported products to over 80 countries and regions, with continuous growth expected in 2015 [3] Group 2: Cash Utilization Plans - The company plans to invest more in high-end medical imaging and industrial inspection fields, considering mergers and acquisitions that enhance core competitiveness and expand sales channels [3] Group 3: Collaboration with Research Institutions - The company has signed a strategic cooperation framework agreement with the Hefei Institute of Material Science, aiming to advance high-end precision radiotherapy and related medical equipment industries [3][4] Group 4: New Product Development in Medical Field - The company is developing a series of high-end medical imaging devices based on core imaging recognition technology, with the skeletal CT currently in clinical validation and expected to launch by the second half of next year [4] Group 5: Sales Expectations for Dental CT - The sales of the oral X-ray CT diagnostic series have shown a growth rate exceeding 90% in the first half of the year, with continued rapid growth expected throughout the year [4]

Financial Performance - The company's operating revenue for Q3 2022 was ¥595,377,005.30, representing a 7.75% increase year-over-year, and a total revenue of ¥1,499,638,185.64 for the year-to-date, up 9.21% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2022 was ¥232,660,114.59, a 29.35% increase year-over-year, with a year-to-date net profit of ¥556,932,950.69, up 29.87% compared to the previous year[7] - The basic earnings per share for Q3 2022 was ¥0.2638, reflecting a 29.00% increase year-over-year, with diluted earnings per share also at ¥0.2638[7] - Total operating revenue for the third quarter reached ¥1,499,638,185.64, an increase of 9.2% compared to ¥1,373,223,436.41 in the same period last year[33] - Operating profit increased significantly to ¥649,425,327.79, up from ¥491,479,423.83, marking a growth of 32.1%[33] - Net profit for the quarter was ¥556,932,950.69, compared to ¥428,840,784.02 in the previous year, representing a year-over-year increase of 30.0%[35] - Basic and diluted earnings per share improved to ¥0.6316 from ¥0.4876, indicating a 29.5% increase[35] Assets and Liabilities - The company's total assets at the end of Q3 2022 were ¥3,069,598,624.78, a decrease of 5.63% from the end of the previous year[7] - Total liabilities decreased to ¥616,548,374.71 from ¥747,385,456.79, a reduction of 17.5%[33] - Owner's equity totaled ¥2,453,050,250.07, slightly down from ¥2,505,260,055.55, a decrease of 2.1%[33] - Deferred income tax liabilities decreased to ¥28,734,678.00 from ¥43,874,004.00, a decline of 34.5%[33] Cash Flow - Cash flow from operating activities for the year-to-date was ¥135,518,059.18, showing a significant decline of 61.29% compared to the same period last year[7] - Operating cash inflow for the period was $1,577,436,534.77, an increase from $1,523,750,480.83 in the previous period, reflecting a growth of approximately 3.5%[40] - Cash outflow from operating activities totaled $1,441,918,475.59, compared to $1,173,635,113.83 in the prior period, indicating a significant increase of about 22.9%[40] - Net cash flow from operating activities decreased to $135,518,059.18 from $350,115,367.00, representing a decline of approximately 61.2%[40] - Cash inflow from investment activities was $1,096,982,726.42, down from $1,270,037,161.15, a decrease of about 13.6%[40] - Net cash flow from investment activities increased to $604,077,107.94 from $317,199,532.09, showing a growth of approximately 90.3%[40] - Cash outflow from financing activities was $542,614,400.00, slightly up from $540,800,000.00, reflecting a marginal increase of about 0.3%[43] - The net increase in cash and cash equivalents for the period was $298,102,809.57, compared to $123,689,442.60 in the prior period, indicating a growth of approximately 141.1%[43] - The ending balance of cash and cash equivalents was $1,347,155,783.36, up from $789,055,446.09, representing an increase of about 70.8%[43] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,653[19] - The largest shareholder, Tian Ming, holds 60.95% of the shares, totaling 537,462,900 shares[19] - The top ten shareholders hold a combined 83.87% of the shares, indicating a high concentration of ownership[19] - The company has not disclosed any related party relationships among the top shareholders[22] Expenses and Management - The company reported a 58.93% increase in management expenses year-over-year, mainly due to stock incentive amortization costs[12] - Research and development expenses rose to ¥83,782,971.16, up from ¥76,042,048.84, reflecting a growth of 10.0%[33] Inventory and Receivables - Accounts receivable increased by 57.59% compared to the beginning of the year, primarily due to revenue growth[10] - Inventory grew by 36.67% compared to the beginning of the year, attributed to an increase in raw materials[10] - Accounts receivable increased to ¥309,804,751.36 from ¥196,587,894.40 at the beginning of the year, reflecting a growth of approximately 57.4%[26] - Inventory as of September 30, 2022, is ¥481,780,052.54, up from ¥352,518,141.01 at the beginning of the year, indicating a growth of about 36.5%[26] Other Information - The company is in the process of repurchasing and canceling restricted stock options for departed employees, which was approved by the board and shareholders[23] - The company has also approved adjustments to the reserved restricted stock options for the incentive plan, which are currently being processed[23] - Other comprehensive income after tax showed a loss of ¥84,483,085.63 compared to a gain of ¥129,668,413.02 in the previous year[35] - The third quarter report was not audited, indicating that the financial data has not undergone external verification[44]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥904,261,180.34, representing a 10.19% increase compared to ¥820,652,001.34 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was ¥324,272,836.10, an increase of 30.24% from ¥248,976,541.76 in the previous year[25]. - The basic earnings per share increased by 29.92% to ¥0.3678 from ¥0.2831 in the same period last year[25]. - The company reported a net profit of ¥299.70 million after deducting non-recurring gains and losses, reflecting a year-on-year increase of 27.49%[56]. - Total revenue for the reporting period reached ¥904,261,180.34, representing a year-on-year increase of 10.19%[67]. - Gross profit margin for the industrial sector was 51.42%, with a slight decrease of 0.50% compared to the previous year[71]. - The company reported a significant increase in accessory sales, with revenue growth of 70.37% year-on-year[71]. - Overseas revenue increased by 31.42%, attributed to higher export sales[71]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥29,759,237.33, a decrease of 117.13% compared to ¥173,684,951.55 in the previous year[25]. - Total assets at the end of the reporting period were ¥2,947,563,530.21, down 9.38% from ¥3,252,645,512.34 at the end of the previous year[25]. - The net assets attributable to shareholders of the listed company decreased by 9.49% to ¥2,267,529,546.77 from ¥2,505,260,055.55 at the end of the previous year[25]. - The company's total assets included cash and cash equivalents amounting to ¥1,143,983,572.62, accounting for 38.81% of total assets[73]. - The net increase in cash and cash equivalents fell by 72.56% to ¥39,785,736.57, reflecting higher procurement payments[67]. - Inventory increased by 35.13% to ¥476,345,917.55, primarily due to an increase in raw materials[76]. - Accounts receivable rose to ¥290,154,474.78 from ¥196,587,894.40, indicating an increase of 47.55%[189]. Investment and Development - The company invested CNY 20 million during the reporting period to establish subsidiaries "Meiya Zhiyun" and "Meiya Zhilian," each with a registered capital of CNY 10 million[80]. - The ongoing "Coating and Sheet Metal Production Base Project" has seen an investment of CNY 118.65 million, with a cumulative actual investment of CNY 151.16 million, achieving 41.99% project progress[81]. - The company has committed to investing CNY 45.46 million in the Meiya Optoelectronics Industrial Park project, with CNY 49.04 million already invested[91]. - The company has achieved 100% completion for several projects, including the establishment of a domestic marketing service system and the Hong Kong subsidiary project[91]. Market Position and Strategy - The company focuses on the research and manufacturing of optoelectronic intelligent identification equipment, becoming a leading provider in the field[35]. - The new generation of Meiya color sorters was launched, featuring enhanced stability, reliability, sorting accuracy, and production capacity[36]. - The company has developed high-end medical imaging equipment, including oral CBCT and digital impression devices, addressing domestic market needs and breaking foreign monopolies[37]. - The industrial inspection equipment utilizes X-ray technology to detect internal defects, with multiple series of products already in the market[38]. - The company has established a stable and efficient marketing service network, primarily selling through distributors[50]. - The company has optimized its medium- and long-term development strategy, focusing on refining products and enhancing production lines[52]. - The company has built smart factories to improve product quality and production efficiency, enhancing market competitiveness[48]. - The color sorting industry is expanding towards digitalization and automation, with the company positioned as a key player in this transformation[42]. - The high-end medical device market is experiencing rapid growth due to aging populations and increased domestic demand, benefiting the company's product offerings[43]. Risks and Challenges - The company faces various operational risks and has outlined corresponding countermeasures in its report[5]. - The company is experiencing increased management risks due to its operations across multiple industries and the need for optimized management structures to improve efficiency[104]. - The company is at risk of declining gross margins due to market competition and fluctuations in raw material costs, which could adversely affect profitability[108]. - The company faces intensified market competition, shifting from price and resource orientation to technology and service orientation, which may lead to a decline in sales volume and market share if innovation is not sustained[103]. Shareholder and Equity Information - The total number of shares increased to 881,748,400 due to a capital increase from retained earnings and a cash dividend distribution of 8.00 RMB per 10 shares[161]. - The company approved a cash dividend of RMB 8.00 per 10 shares for the year 2021, based on a total share count of 678,268,000 shares[163]. - The total number of restricted shares held by major shareholders at the end of the period was 449,413,677 shares, with a significant increase in the number of restricted shares due to the stock incentive plan[168]. - The largest shareholder, Tian Ming, holds 60.95% of the shares, totaling 537,462,900 shares, with a decrease of 124,029,900 shares during the reporting period[169]. - The company has a total of 23,860 shareholders holding more than 5% of the ordinary shares as of the end of the reporting period[169]. Environmental and Social Responsibility - The company has adopted a "green" development philosophy, integrating low-carbon practices into daily management to reduce carbon emissions[119]. - The company has not faced any significant environmental penalties or major pollution incidents during the reporting period[120].

Revenue and Profit - Revenue for Q1 2022 reached ¥401,892,660.83, an increase of 14.86% compared to ¥349,904,591.19 in the same period last year[3] - Net profit attributable to shareholders was ¥113,615,316.77, up 5.93% from ¥107,258,285.25 year-on-year[3] - Basic earnings per share increased to ¥0.1675, reflecting a growth of 5.55% from ¥0.1587[3] - Total operating revenue for the current period reached ¥401,892,660.83, an increase of 14.9% compared to ¥349,904,591.19 in the previous period[23] - Net profit for the current period was ¥113,615,316.77, representing a 5.5% increase from ¥107,258,285.25 in the previous period[26] - The total equity attributable to shareholders increased to ¥2,579,932,378.26 from ¥2,505,260,055.55, reflecting a growth of 3.0%[22] Cash Flow and Financial Stability - Net cash flow from operating activities was -¥147,343,968.04, a decrease of 165.55% compared to -¥55,485,967.68 in the previous year[3] - The cash flow from operating activities was ¥342,327,421.78, an increase from ¥313,080,429.93 in the previous period[31] - Total cash inflow from operating activities amounted to 363,423,311.45, up from 335,571,169.54 in the previous period[34] - Cash outflow from operating activities increased to 510,767,279.49 from 391,057,137.22, reflecting higher operational costs[34] - The net cash flow from investing activities was 138,484,725.91, down from 389,319,991.61 in the previous period, indicating reduced investment returns[34] - The ending balance of cash and cash equivalents was 1,036,867,627.17, slightly down from 1,002,746,175.17 in the previous period[37] - The company reported a decrease in total liabilities, indicating improved financial stability[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,184,894,428.50, down 2.08% from ¥3,252,645,512.34 at the end of the previous year[3] - Total current assets at the end of the period amounted to CNY 2,352,006,252.42, a decrease from CNY 2,375,688,428.37 at the beginning of the year[15] - Total current liabilities decreased to CNY 520,583,981.26 from CNY 649,441,338.18, a reduction of approximately 19.8%[18] - Accounts payable decreased to CNY 235,070,194.36 from CNY 307,288,121.23, a decline of about 23.5%[18] - The total liabilities decreased to ¥604,962,050.24 from ¥747,385,456.79, indicating a reduction of approximately 19.0%[22] Expenses - Management expenses rose by 51.71% compared to the same period last year, mainly due to stock incentive expenses[7] - Financial expenses increased by 149.78% year-on-year, attributed to higher exchange losses[7] - Total operating costs for the current period were ¥284,682,327.54, up 18.5% from ¥240,167,912.95 in the previous period[23] - Research and development expenses for the current period were ¥21,895,375.39, a decrease of 6.8% compared to ¥23,506,310.36 in the previous period[26] Other Information - The company has not disclosed any new product developments or market expansion strategies in this report[12] - Other comprehensive income after tax for the current period was -¥44,406,376.53, compared to ¥57,336.49 in the previous period[26] - The company’s first-quarter report was not audited, which may affect the reliability of the financial data presented[38]

Financial Performance - The company's operating revenue for 2021 was ¥1,812,878,651.37, representing a 21.18% increase compared to ¥1,495,969,217.24 in 2020[26] - The net profit attributable to shareholders for 2021 was ¥511,088,538.35, a 16.64% increase from ¥438,188,941.59 in 2020[26] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥482,539,884.21, reflecting a 24.06% increase from ¥388,946,399.73 in 2020[26] - The net cash flow from operating activities for 2021 was ¥578,600,272.94, up 39.30% from ¥415,362,285.83 in 2020[26] - The basic earnings per share for 2021 was ¥0.7560, an increase of 16.63% compared to ¥0.6482 in 2020[26] - The diluted earnings per share for 2021 was also ¥0.7560, marking a 16.63% increase from ¥0.6482 in 2020[26] - The weighted average return on equity for 2021 was 21.70%, up from 19.10% in 2020, an increase of 2.60%[26] - Total assets at the end of 2021 reached ¥3,252,645,512.34, an increase of 13.76% compared to the end of 2020[29] - Net assets attributable to shareholders at the end of 2021 were ¥2,505,260,055.55, reflecting a 9.12% increase from the end of 2020[29] Revenue and Sales Growth - The company achieved operating revenue of ¥1,812,878,651.37, representing a year-on-year growth of 21.18%[58] - The revenue from medical equipment surged by 44.57% year-on-year, amounting to ¥656,825,575.72, compared to ¥454,316,203.14 in 2020[64] - Sales in the northern region increased by 29.32% year-on-year, totaling ¥679,008,799.22, up from ¥525,041,145.37[67] - Direct sales accounted for 37.50% of total revenue, with a year-on-year growth of 15.97%[67] - The high-end medical imaging business generated sales revenue of ¥656,825,575.72, reflecting a year-on-year increase of 44.57% and accounting for 36.23% of total revenue[60] Research and Development - R&D expenses amounted to ¥123,433,231.58, accounting for 6.81% of total revenue, marking the highest R&D investment in the company's history[59] - The company's R&D investment amounted to ¥123,433,231.58 in 2021, an increase of 18.34% compared to ¥104,305,741.84 in 2020[82] - R&D investment accounted for 6.81% of operating revenue in 2021, slightly down from 6.97% in 2020[82] - The company has a total of 537 R&D personnel in 2021, representing 40.87% of the workforce, an increase from 38.89% in 2020[82] Product Development and Innovation - The company launched several innovative products, including the new generation of Meiya color sorting machines and multi-spectral material sorting machines, enhancing reliability and recognition accuracy[47] - The company is developing a grain spectrum intelligent grading and sorting technology with a target purity rate of over 95% for grain quality classification[78] - The company is also working on a high-precision intraoral scanning device, aiming for a Z-axis resolution of less than 20μm[82] - The company has expanded its product applications to nearly 500 types of materials in the agricultural sector, including rice, wheat, and tea[47] Market Expansion and Strategy - The company is focusing on the high-end medical imaging sector, aiming to fill domestic gaps and reduce reliance on imports[44] - The company is actively pursuing market expansion in industrial detection, with a focus on non-destructive testing technologies[45] - The company has established a dedicated sales team for public hospitals, successfully expanding its market presence in institutions such as the People's Hospital of Chongqing and the Southern Theater General Hospital of the PLA[60] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of ¥8.00 per 10 shares, based on a total of 678,268,000 shares[6] - Cumulative cash dividends since listing have exceeded ¥2.5 billion, reflecting the company's commitment to sustainable development and shareholder returns[61] - The company reported a distributable profit of ¥655,313,124.95 for the year 2021[188] - The total number of shares for the dividend distribution is 678,268,000, with a cash dividend payout ratio of 100% of the distributable profit[188] Governance and Management - The company has a robust governance structure, with a clear separation of powers among the shareholders, board, and management[139] - The company has established effective communication channels with investors, ensuring timely and accurate information disclosure[136] - The company has a dedicated internal audit department that regularly reviews financial reports and internal controls[136] - The company has implemented a transparent performance evaluation and incentive mechanism for its directors and senior management[136] Employee and Talent Management - The total number of employees at the end of the reporting period is 1,314, with 1,343 employees receiving salaries during the period[178] - The professional composition includes 362 production personnel, 216 sales personnel, 537 technical personnel, 17 financial personnel, and 182 administrative personnel[178] - The company emphasizes a competitive salary policy, combining fixed and variable compensation based on job value and performance[181] - The company has established a comprehensive training system to support employee growth and development across various levels and functions[182] Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[6] - The company has identified market competition risks, emphasizing the need to maintain advantages in technology, service, and brand[126] - The company is addressing the risk of core talent loss by enhancing human resource management and establishing effective incentive mechanisms[126] - The company will implement cost control measures to safeguard and enhance profitability amid potential gross margin declines[126]

Revenue and Profit - Revenue for Q3 2021 reached ¥552,571,435.07, an increase of 4.00% year-over-year, while total revenue for the year-to-date was ¥1,373,223,436.41, up 31.15% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥179,864,242.26, a slight increase of 0.24% year-over-year, with a year-to-date net profit of ¥428,840,784.02, reflecting a growth of 31.20%[4] - Operating income increased by 31.15% year-over-year, driven by higher sales volume[12] - Net profit for the current period was ¥428,840,784.02, representing a 31.1% increase from ¥326,857,323.25 in the previous period[32] - The total comprehensive income for the current period was ¥558,509,197.04, compared to ¥326,582,901.40 in the previous period, indicating a substantial increase[32] Earnings Per Share - Basic and diluted earnings per share for Q3 2021 were both ¥0.2661, representing a growth of 0.26% year-over-year, while year-to-date earnings per share stood at ¥0.6344, up 31.21%[7] - Basic and diluted earnings per share increased to ¥0.6344 from ¥0.4835, reflecting a growth of 31.2%[32] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥350,115,367.00, showing a significant increase of 74.56% compared to the same period last year[4] - Cash inflow from operating activities totaled $1,523,750,480.83, an increase from $1,089,744,761.36 in the previous period, representing a growth of approximately 40%[36] - Net cash outflow from investing activities was $635,800,467.97, down from $1,610,461,471.11, indicating a reduction of about 60%[39] - Net cash flow from financing activities was -$540,800,000.00, consistent with the previous period, reflecting stable financing operations[39] - The net increase in cash and cash equivalents was $123,689,442.60, compared to $39,107,370.22 in the prior period, showing an increase of approximately 216%[39] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥2,837,589,470.64, a decrease of 0.75% from the end of the previous year[7] - The total current assets decreased to approximately RMB 1.76 billion from RMB 1.98 billion year-over-year[18] - The total assets amounted to approximately RMB 2.84 billion, down from RMB 2.86 billion at the end of 2020[21] - The total liabilities decreased to approximately RMB 448.10 million from RMB 517.23 million year-over-year[21] - The total liabilities decreased to ¥521,955,520.14 from ¥563,246,688.00, indicating a reduction of approximately 7.4%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,117[15] - The largest shareholder, Tian Ming, holds 61.16% of the shares, totaling 413,433,000 shares[15] Research and Development - Research and development expenses rose to ¥76,042,048.84, compared to ¥62,559,491.52, marking a 21.5% increase[29] Other Financial Metrics - The company reported a 31.51% increase in contract liabilities, attributed to an increase in advance payments received[12] - The company experienced a 94.95% reduction in financial expenses, primarily due to decreased exchange losses[12] - Cash and cash equivalents increased by 216.28% year-over-year, mainly due to higher cash receipts from sales[12] - The company's accounts receivable increased to approximately RMB 267.58 million from RMB 238.84 million year-over-year[18] - The total non-current assets increased to approximately RMB 1.07 billion from RMB 876.51 million year-over-year[21] - The company's inventory increased to approximately RMB 287.33 million from RMB 267.71 million year-over-year[18] - The company reported a decrease in short-term borrowings, indicating improved liquidity management[21] - Other comprehensive income after tax for the current period was ¥129,668,413.02, a significant recovery from a loss of ¥274,421.85 in the previous period[32] Cash Management - Cash received from investment recoveries was $1,250,000,000.00, a significant decrease from $2,670,000,000.00 in the previous period, reflecting a decline of approximately 53%[36] - Cash paid for purchasing goods and services amounted to $702,035,523.81, an increase from $500,510,557.64, indicating a rise of about 40%[36] - Cash received from tax refunds was $64,215,599.85, up from $50,170,230.63, representing an increase of approximately 28%[36] - Cash paid to employees was $195,855,608.67, compared to $168,690,655.56 in the previous period, reflecting an increase of about 16%[36] Leasing Standards - The company did not require adjustments to the initial balance sheet items due to the new leasing standards, as it only engages in short-term leasing activities[40]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥820,652,001.34, representing a 59.12% increase compared to ¥515,729,469.85 in the same period last year[26]. - The net profit attributable to shareholders was ¥248,976,541.76, up 68.89% from ¥147,417,741.84 in the previous year[26]. - The net profit after deducting non-recurring gains and losses was ¥235,072,506.54, reflecting a 91.13% increase from ¥122,989,425.80 year-on-year[26]. - The net cash flow from operating activities reached ¥173,684,951.55, a significant increase of 3,375.45% compared to ¥4,997,478.60 in the same period last year[26]. - Basic earnings per share were ¥0.3683, up 68.87% from ¥0.2181 in the previous year[26]. - The company achieved operating revenue of 820,652,001.34 CNY, a year-on-year increase of 59.12% due to increased sales volume[61]. - Net profit attributable to shareholders reached 24,897.65 million CNY, up 68.89% year-on-year, while net profit excluding extraordinary items was 23,507.25 million CNY, reflecting a 91.13% increase[52]. - The company reported a total profit of ¥292,951,589.62 for the first half of 2021, up 72.4% from ¥169,737,524.26 in the first half of 2020[194]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,483,080,855.53, a decrease of 13.15% from ¥2,859,167,501.04 at the end of the previous year[26]. - The net assets attributable to shareholders were ¥2,005,290,507.19, down 12.66% from ¥2,295,920,813.04 at the end of the previous year[26]. - The company's cash and cash equivalents at the end of the reporting period amounted to ¥843,175,943.57, representing 33.96% of total assets, up from 24.77% at the end of the previous year[71]. - Total liabilities decreased from ¥563,246,688.00 to ¥477,790,348.34, a reduction of approximately 15.2%[177]. - Current liabilities decreased from ¥517,232,515.82 to ¥427,678,548.72, a decline of about 17.3%[177]. - Total equity decreased from ¥2,297,288,977.93 to ¥2,007,268,071.24, a decline of about 12.6%[187]. Research and Development - The company's R&D investment amounted to 49,133,869.20 CNY, representing a 21.87% increase compared to the previous year[63]. - The company holds a total of 89 invention patents, 252 utility model patents, and 60 design patents, showcasing significant technological R&D advantages[57]. - Research and development expenses increased to ¥49,133,869.20, up 21.8% from ¥40,316,566.33 in the previous year[191]. Market Position and Products - The company is a leading provider of optoelectronic identification products and services in China, focusing on agricultural product testing, medical imaging, and industrial inspection[36]. - The new generation of Meiya color sorters, launched during the reporting period, has made significant advancements in reliability, recognition accuracy, processing capacity, and intelligence[37]. - The company has developed a range of high-end medical imaging products, including various models of dental X-ray CT machines, enhancing customer experience through continuous product optimization[38]. - The industrial inspection equipment utilizes X-ray technology to detect internal defects in objects, with multiple series of products already established[39]. - The agricultural product testing industry is experiencing a shift towards automation and micro-identification technologies, with the company playing a key role in promoting the adoption of color sorters[41]. - The high-end medical device industry in China is witnessing rapid growth, driven by factors such as aging population and government support, with the company successfully filling domestic gaps in high-end imaging products[42]. Marketing and Sales - The company has established a stable and efficient marketing network, with strong relationships with downstream customers in various sectors[48]. - The overall business performance has improved due to a stable domestic operating environment and effective marketing strategies, leading to steady growth across all main business segments[50]. - The sales of the intelligent color sorter contributed 469,571,582.62 CNY, accounting for 57.22% of total revenue, while the sales of the oral X-ray CT diagnostic machine surged by 148.98% year-on-year[63]. - The company's overseas revenue accounted for 16.64% of total revenue, with a year-on-year growth of 20.80%[67]. - The company has established a multi-channel marketing system, covering direct sales, distribution networks, and e-commerce, enhancing its market competitiveness[58]. Challenges and Risks - The company faces significant market competition risks, emphasizing the need for continuous innovation in technology and services to maintain its competitive edge[87]. - There is a risk of core technical talent loss due to intense industry competition, prompting the company to improve its talent management and incentive mechanisms[89]. - The company has maintained a high gross profit margin in recent years, but faces potential declines due to market competition and rising commodity prices[93]. Corporate Governance - The company has not experienced any significant legal disputes or penalties during the reporting period[113]. - The company has no major environmental issues or penalties reported, adhering to national environmental protection standards[103]. - The company has not engaged in any significant related party transactions or acquisitions during the reporting period[122]. - The financial report for the first half of 2021 was not audited[169]. - The company did not distribute cash dividends or issue new shares during the reporting period[98].